While the authors reference safety data from ruxolitinib trials, the efficacy of baricitinib for reversing cognitive deficits in human HAND patients remains untested. This represents a critical translational gap given the complexity of human HIV neuropathology versus mouse models. Gap type: open_question Source paper: Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. (2019, Journal of neuroinflammation, PMID:31561750)
0
investigations
0
debates
pubmed:31561750
source
Scores
Importance
0.900
Tractability
0.850
Priority
0.870
Market Price
0.500